Molecular Monitoring in CML: Known Knowns, Known Unknowns, and Unknown Unknowns
This information was originally presented on September 19, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Differentiate the clinical evidence regarding the prognostic significance of early molecular response to TKI therapy and the importance of molecular monitoring with QPCR (IS)
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- 0.75 Participation
- 0.63 Nurse
- 0.75 Pharmacist
- 0.75 Physician